The global diabetes care drugs market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth in this market is attributed to the increasing prevalence of diabetes and the rising awareness about its treatment. The oral antidiabetic drugs segment accounted for the largest share in 2018, followed by insulin and noinsulin injectable drugs segments. Oral antidiabetic drugs segment is expected to maintain its dominance throughout the forecast period due to their easy availability and affordability as compared with insulin injections. North America accounted for the largest share in 2018, followed by Europe and Asia Pacific respectively.
Some Of The Growth Factors Of This Market:
- In addition, rising awareness about the benefits of these drugs among patients and physicians is also expected to fuel demand for these products in the near future.
- Furthermore, technological advancements in drug delivery systems such as inhalers and patches are anticipated to provide an impetus for growth in this market over the forecast period (2017-2022) 4) Increasing incidence rates for type 2 diabetes globally will drive demand for these products over the next few years.
Industry Growth Insights published a new data on “Diabetes Care Drugs Market”. The research report is titled “Diabetes Care Drugs Market research by Types (Oral Anti-diabetic Drugs, Insulins, Non-insulin Injectable Drugs, Other), By Applications (Hospital, Medical Research Institute, Clinic, Other), By Players/Companies Novo Nordisk, Sanofi, Eli Lilly, Biocon, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Mylan, Pfizer, Johnson & Johnson, Merck, Novartis, Astellas, Teva”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetes Care Drugs Market Research Report
By Type
Oral Anti-diabetic Drugs, Insulins, Non-insulin Injectable Drugs, Other
By Application
Hospital, Medical Research Institute, Clinic, Other
By Companies
Novo Nordisk, Sanofi, Eli Lilly, Biocon, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Mylan, Pfizer, Johnson & Johnson, Merck, Novartis, Astellas, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
232
Number of Tables & Figures
163
Customization Available
Yes, the report can be customized as per your need.
Global Diabetes Care Drugs Market Report Segments:
The global Diabetes Care Drugs market is segmented on the basis of:
Types
Oral Anti-diabetic Drugs, Insulins, Non-insulin Injectable Drugs, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Medical Research Institute, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Sanofi
- Eli Lilly
- Biocon
- AstraZeneca
- Bristol Myers Squibb
- Boehringer Ingelheim
- Mylan
- Pfizer
- Johnson & Johnson
- Merck
- Novartis
- Astellas
- Teva
Highlights of The Diabetes Care Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral Anti-diabetic Drugs
- Insulins
- Non-insulin Injectable Drugs
- Other
- By Application:
- Hospital
- Medical Research Institute
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetes Care Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetes care drugs are medications that help to control blood sugar levels in people with diabetes. These drugs can be used alone or in combination with other treatments, such as diet and exercise.
Some of the major companies in the diabetes care drugs market are Novo Nordisk, Sanofi, Eli Lilly, Biocon, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Mylan, Pfizer, Johnson & Johnson, Merck, Novartis, Astellas, Teva.
The diabetes care drugs market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diabetes Care Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diabetes Care Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diabetes Care Drugs Market - Supply Chain
4.5. Global Diabetes Care Drugs Market Forecast
4.5.1. Diabetes Care Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diabetes Care Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diabetes Care Drugs Market Absolute $ Opportunity
5. Global Diabetes Care Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diabetes Care Drugs Market Size and Volume Forecast by Type
5.3.1. Oral Anti-diabetic Drugs
5.3.2. Insulins
5.3.3. Non-insulin Injectable Drugs
5.3.4. Other
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diabetes Care Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diabetes Care Drugs Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Medical Research Institute
6.3.3. Clinic
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diabetes Care Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diabetes Care Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diabetes Care Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diabetes Care Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diabetes Care Drugs Demand Share Forecast, 2019-2026
9. North America Diabetes Care Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diabetes Care Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diabetes Care Drugs Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Medical Research Institute
9.4.3. Clinic
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diabetes Care Drugs Market Size and Volume Forecast by Type
9.7.1. Oral Anti-diabetic Drugs
9.7.2. Insulins
9.7.3. Non-insulin Injectable Drugs
9.7.4. Other
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diabetes Care Drugs Demand Share Forecast, 2019-2026
10. Latin America Diabetes Care Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diabetes Care Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diabetes Care Drugs Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Medical Research Institute
10.4.3. Clinic
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diabetes Care Drugs Market Size and Volume Forecast by Type
10.7.1. Oral Anti-diabetic Drugs
10.7.2. Insulins
10.7.3. Non-insulin Injectable Drugs
10.7.4. Other
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diabetes Care Drugs Demand Share Forecast, 2019-2026
11. Europe Diabetes Care Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diabetes Care Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diabetes Care Drugs Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Medical Research Institute
11.4.3. Clinic
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diabetes Care Drugs Market Size and Volume Forecast by Type
11.7.1. Oral Anti-diabetic Drugs
11.7.2. Insulins
11.7.3. Non-insulin Injectable Drugs
11.7.4. Other
11.8. Bsis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diabetes Care Drugs Demand Share, 2019-2026
12. Asia Pacific Diabetes Care Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diabetes Care Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diabetes Care Drugs Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Medical Research Institute
12.4.3. Clinic
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diabetes Care Drugs Market Size and Volume Forecast by Type
12.7.1. Oral Anti-diabetic Drugs
12.7.2. Insulins
12.7.3. Non-insulin Injectable Drugs
12.7.4. Other
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diabetes Care Drugs Demand Share, 2019-2026
13. Middle East & Africa Diabetes Care Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diabetes Care Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diabetes Care Drugs Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Medical Research Institute
13.4.3. Clinic
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diabetes Care Drugs Market Size and Volume Forecast by Type
13.7.1. Oral Anti-diabetic Drugs
13.7.2. Insulins
13.7.3. Non-insulin Injectable Drugs
13.7.4. Other
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diabetes Care Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Diabetes Care Drugs Market: Market Share Analysis
14.2. Diabetes Care Drugs Distributors and Customers
14.3. Diabetes Care Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novo Nordisk
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Sanofi
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Biocon
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bristol Myers Squibb
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Boehringer Ingelheim
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Mylan
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Pfizer
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Johnson & Johnson
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Merck
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Novartis
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Astellas
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Teva
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
